Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Major Manufacturers Covered in This Report
• 1.3 Market Segment by Type
  • 1.3.1 Global Peptide Antibiotics Market Size Growth Rate by Type (2019-2025)
  • 1.3.2 Ribosomal Synthesized Peptide Antibiotics
  • 1.3.3 Non-Ribosomally Synthesized Peptide Antibiotics
• 1.4 Market Segment by Application
  • 1.4.1 Global Peptide Antibiotics Market Share by Application (2019-2025)
  • 1.4.2 Pharma & Healthcare
  • 1.4.3 Food Industry
  • 1.4.4 Commodities
  • 1.4.5 Other
• 1.5 Study Objectives
• 1.6 Years Considered

2 Global Growth Trends

• 2.1 Global Peptide Antibiotics Market Size
  • 2.1.1 Global Peptide Antibiotics Revenue 2014-2025
  • 2.1.2 Global Peptide Antibiotics Sales 2014-2025
• 2.2 Peptide Antibiotics Growth Rate by Regions
  • 2.2.1 Global Peptide Antibiotics Sales by Regions 2014-2019
  • 2.2.2 Global Peptide Antibiotics Revenue by Regions 2014-2019
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers

3 Market Share by Manufacturers

• 3.1 Peptide Antibiotics Sales by Manufacturers
  • 3.1.1 Peptide Antibiotics Sales by Manufacturers 2014-2019
  • 3.1.2 Peptide Antibiotics Sales Market Share by Manufacturers 2014-2019
• 3.2 Revenue by Manufacturers
  • 3.2.1 Peptide Antibiotics Revenue by Manufacturers (2014-2019)
  • 3.2.2 Peptide Antibiotics Revenue Share by Manufacturers (2014-2019)
  • 3.2.3 Global Peptide Antibiotics Market Concentration Ratio (CR5 and HHI)
• 3.3 Peptide Antibiotics Price by Manufacturers
• 3.4 Key Manufacturers Peptide Antibiotics Plants/Factories Distribution and Area Served
• 3.5 Date of Key Manufacturers Enter into Peptide Antibiotics Market
• 3.6 Key Manufacturers Peptide Antibiotics Product Offered
• 3.7 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Sales and Revenue for Each Type
  • 4.1.1 Ribosomal Synthesized Peptide Antibiotics Sales and Revenue (2014-2019)
  • 4.1.2 Non-Ribosomally Synthesized Peptide Antibiotics Sales and Revenue (2014-2019)
• 4.2 Global Peptide Antibiotics Sales Market Share by Type
• 4.3 Global Peptide Antibiotics Revenue Market Share by Type
• 4.4 Peptide Antibiotics Price by Type

5 Market Size by Application

• 5.1 Overview
• 5.2 Global Peptide Antibiotics Sales by Application

6 United States

• 6.1 United States Peptide Antibiotics Breakdown Data by Company
• 6.2 United States Peptide Antibiotics Breakdown Data by Type
• 6.3 United States Peptide Antibiotics Breakdown Data by Application

7 European Union

• 7.1 European Union Peptide Antibiotics Breakdown Data by Company
• 7.2 European Union Peptide Antibiotics Breakdown Data by Type
• 7.3 European Union Peptide Antibiotics Breakdown Data by Application

8 China

• 8.1 China Peptide Antibiotics Breakdown Data by Company
• 8.2 China Peptide Antibiotics Breakdown Data by Type
• 8.3 China Peptide Antibiotics Breakdown Data by Application

9 Rest of World

• 9.1 Rest of World Peptide Antibiotics Breakdown Data by Company
• 9.2 Rest of World Peptide Antibiotics Breakdown Data by Type
• 9.3 Rest of World Peptide Antibiotics Breakdown Data by Application
• 9.4 Rest of World Peptide Antibiotics Breakdown Data by Countries
  • 9.4.1 Rest of World Peptide Antibiotics Sales by Countries
  • 9.4.2 Rest of World Peptide Antibiotics Revenue by Countries
  • 9.4.3 Japan
  • 9.4.4 Korea
  • 9.4.5 India
  • 9.4.6 Southeast Asia

10 Company Profiles

• 10.1 Pfizer
  • 10.1.1 Pfizer Company Details
  • 10.1.2 Company Description and Business Overview
  • 10.1.3 Sales, Revenue and Market Share of Peptide Antibiotics
  • 10.1.4 Peptide Antibiotics Product Introduction
  • 10.1.5 Pfizer Recent Development
• 10.2 Novartis
  • 10.2.1 Novartis Company Details
  • 10.2.2 Company Description and Business Overview
  • 10.2.3 Sales, Revenue and Market Share of Peptide Antibiotics
  • 10.2.4 Peptide Antibiotics Product Introduction
  • 10.2.5 Novartis Recent Development
• 10.3 GlaxoSmithKline
  • 10.3.1 GlaxoSmithKline Company Details
  • 10.3.2 Company Description and Business Overview
  • 10.3.3 Sales, Revenue and Market Share of Peptide Antibiotics
  • 10.3.4 Peptide Antibiotics Product Introduction
  • 10.3.5 GlaxoSmithKline Recent Development
• 10.4 Eli Lilly
  • 10.4.1 Eli Lilly Company Details
  • 10.4.2 Company Description and Business Overview
  • 10.4.3 Sales, Revenue and Market Share of Peptide Antibiotics
  • 10.4.4 Peptide Antibiotics Product Introduction
  • 10.4.5 Eli Lilly Recent Development
• 10.5 Theravance
  • 10.5.1 Theravance Company Details
  • 10.5.2 Company Description and Business Overview
  • 10.5.3 Sales, Revenue and Market Share of Peptide Antibiotics
  • 10.5.4 Peptide Antibiotics Product Introduction
  • 10.5.5 Theravance Recent Development
• 10.6 Vicuron Pharmaceuticals
  • 10.6.1 Vicuron Pharmaceuticals Company Details
  • 10.6.2 Company Description and Business Overview
  • 10.6.3 Sales, Revenue and Market Share of Peptide Antibiotics
  • 10.6.4 Peptide Antibiotics Product Introduction
  • 10.6.5 Vicuron Pharmaceuticals Recent Development
• 10.7 Savara Pharmaceuticals
  • 10.7.1 Savara Pharmaceuticals Company Details
  • 10.7.2 Company Description and Business Overview
  • 10.7.3 Sales, Revenue and Market Share of Peptide Antibiotics
  • 10.7.4 Peptide Antibiotics Product Introduction
  • 10.7.5 Savara Pharmaceuticals Recent Development
• 10.8 AMP Therapeutics
  • 10.8.1 AMP Therapeutics Company Details
  • 10.8.2 Company Description and Business Overview
  • 10.8.3 Sales, Revenue and Market Share of Peptide Antibiotics
  • 10.8.4 Peptide Antibiotics Product Introduction
  • 10.8.5 AMP Therapeutics Recent Development
• 10.9 Hospira
  • 10.9.1 Hospira Company Details
  • 10.9.2 Company Description and Business Overview
  • 10.9.3 Sales, Revenue and Market Share of Peptide Antibiotics
  • 10.9.4 Peptide Antibiotics Product Introduction
  • 10.9.5 Hospira Recent Development
• 10.10 Kasten
  • 10.10.1 Kasten Company Details
  • 10.10.2 Company Description and Business Overview
  • 10.10.3 Sales, Revenue and Market Share of Peptide Antibiotics
  • 10.10.4 Peptide Antibiotics Product Introduction
  • 10.10.5 Kasten Recent Development
• 10.11 Madam Therapeutics
• 10.12 Phosphagenics
• 10.13 Pacgen Life Science Corporation

11 Value Chain and Sales Channels Analysis

• 11.1 Value Chain Analysis
• 11.2 Sales Channels Analysis
  • 11.2.1 Peptide Antibiotics Sales Channels
  • 11.2.2 Peptide Antibiotics Distributors
• 11.3 Peptide Antibiotics Customers

12 Market Forecast

• 12.1 Global Peptide Antibiotics Sales and Revenue Forecast 2019-2025
• 12.2 Global Peptide Antibiotics Sales Forecast by Type
• 12.3 Global Peptide Antibiotics Sales Forecast by Application
• 12.4 Peptide Antibiotics Forecast by Regions
  • 12.4.1 Global Peptide Antibiotics Sales Forecast by Regions 2019-2025
  • 12.4.2 Global Peptide Antibiotics Revenue Forecast by Regions 2019-2025
• 12.5 United States Market Forecast
• 12.6 European Union Market Forecast
• 12.7 China Market Forecast
• 12.8 Rest of World
  • 12.8.1 Japan
  • 12.8.2 Korea
  • 12.8.3 India

13 Research Findings and Conclusion

14 Appendix

• 14.1 Research Methodology
  • 14.1.1 Methodology/Research Approach
    • 14.1.1.1 Research Programs/Design
    • 14.1.1.2 Market Size Estimation
    • 14.1.1.3 Market Breakdown and Data Triangulation
  • 14.1.2 Data Source
    • 14.1.2.1 Secondary Sources
    • 14.1.2.2 Primary Sources
• 14.2 Author Details

In 2019, the market size of Peptide Antibiotics is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Peptide Antibiotics.

This report studies the global market size of Peptide Antibiotics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Peptide Antibiotics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:
Pfizer
Novartis
GlaxoSmithKline
Eli Lilly
Theravance
Vicuron Pharmaceuticals
Savara Pharmaceuticals
AMP Therapeutics
Hospira
Kasten
Madam Therapeutics
Phosphagenics
Pacgen Life Science Corporation

Market Segment by Product Type
Ribosomal Synthesized Peptide Antibiotics
Non-Ribosomally Synthesized Peptide Antibiotics

Market Segment by Application
Pharma & Healthcare
Food Industry
Commodities
Other

Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)

The study objectives are:
To analyze and research the Peptide Antibiotics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Peptide Antibiotics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

In this study, the years considered to estimate the market size of Peptide Antibiotics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025